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Introduction
The success in onychomycoses treatment that has been 
achieved for the last decades allows to provide significant im-
provement of the patients’ life quality.  However, the incidence 
of this disease, late presentation, heredity, long duration of 
contagious period in patients and an increase in the number 
of patients make the improvement of methods used for the 
treatment of onychomycoses one of the current medico-social 
challenges [4, 5].
Nail plate in a healthy person is considered to be essentially 
impervious to mycotic infection. Fungus penetration is usually 
preceded by nail injury, impairment of natural resistance of 
the body associated with immune deficiencies and disorders 
of vital functions resulting in neurotrophic alterations of the 
nail bed [8].
A healthy fingernail plate grows by 2-4.5 mm per month. 
Toenails grow half less slowly, growing on average by 1-2 mm 
per month.  Entire fingernail plate grows over a period of 
4-6 months and toenails require a period 12-18 months [9]. 
Various factors exert impact on the growth rate.  Nails grow 
quicker in children than in adults and quicker in young men 
than in young women but with age this correlation changes. 
Nails in elder people demonstrate the slowest growth rate. 
Nails grow slightly quicker at daytime.  In winter and in people 
who live in areas with colder climate nails grow less slowly. 
Injuries and whole nail plate removal stimulate its formation. 
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Abstract
Background: Onychomycosis is one of the current medico-social challenges.  The article deals with the advantages of combined comprehensive 
therapy rendered to patients with onychomycoses using systemic antimycotics and vitamin agent Wolvit over standard therapeutic regimen determined 
by a comparative study of two groups.
Material and methods: We observed 43 patients with onychomycosis of hands and feet: the main group (33 patients) received Wolvit 5 mg per day and 
systemic antimycotic in standard dosage, control group (10 persons) – systemic antimycotic.  The course of treatment was 1.5 months for onychomycosis 
of the hands and 3 months for onychomycosis of the feet.  All patients underwent a comprehensive clinical and laboratory examination.  Mycological 
research was on the fourth, sixth, eighth, tenth, twelfth and sixteenth weeks of treatment.
Results: The administration of vitamin agent Wolvit together with systemic antimycotics allows to achieve a significant improvement of nail plate 
structure as it acquires even light pink translucent color, glossy surface, smooth and thick free edge, normotrophic structure.  Participation of biothinum 
in the formation of keratine, necessary for the development of hair matrix and nail plate, results in acceleration of healthy nail growth in patients with 
onychomycoses.  Biothinum is also a source of sulphur, which transports sulphur into the skin and its accessory organs, contributing to collagen formation 
and therefore eliminates signs of early hair depigmantation, normalizes sebaceous glands function and exerts a positive impact on the structure of skin 
and its accessory organs (hair, nails).
Conclusions: The obtained results show that the developed complex is effective, safe and allows to achieve both clinical and etiologic recovery.
Key words: Wolvit, vitamins, onychomycosis, systemic antimycotic, nail plate growth.
Hypo- or avitominosis, general severe diseases, which result in 
matrix function deficiency, slow down nail growth rate. Nail 
plate formation is deteriorated when the patient is treated 
with cytostatics [6, 7, 12].
The choice of the best possible method of treatment for 
patients with onychomycosis depends on the character of nail 
plate impairment, type of pathogenic agent, the amount of 
affected nail plates, age of the patient and many other factors. 
But one correlation which remains unchanged in employment 
of local or systemic therapy is the dependence of treatment on 
the nail plate growth rate.  Thus, the longer the affected nail 
plate renews, the higher the risk to develop adverse reactions 
and complications following a prolonged intake of systemic 
antimycotics or a prolonged local exposure to antifungal 
agents (contact dermatitis, eczematization).  
In onychomycoses nail plate growth rate is significantly 
reduced due to thickening and deformation of plates, periph-
eral trophism impairment and insufficient supply of vitamins 
and microelements, which take an active part in the structure 
formation and nail plate growth.  In atrophic onychomycoses 
nail plate growth practically ceases due to partial or complete 
destruction of free edge by mycelium. 
The treatment of onychomycoses takes much time and 
requires thorough monitoring of functional status of the liver 
and bile ducts.  Side effects, possible in case of prolonged 
administration of systemic antimycotics are as follows: dys-
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peptic events (nausea, vomiting, abdominal fullness or pain 
in the abdomen, sometimes loss of appetite, loss or change 
of taste during treatment), allergic reactions (urticaria), 
headache and dizziness, photosensitivity, toxic effects such 
as hepatotoxicity, agranulocytosis, organ of vision impair-
ment and some other [5].  To avoid all the above mentioned 
adverse effects comprehensive treatment of onychomycoses 
should include hepatoprotectors and agents which improve 
nail plate structure and contribute to a quicker nail plate 
growth and this results in the promotion of earlier mycologic 
negative reaction, providing a possibility to reduce the period 
of systemic antimycotics administration and to decrease the 
risk of adverse effects. Biothinum (vitamin H) belongs to the 
agents which exert a positive effect on skin structure and its 
accessory organs [6, 7].
Wolvit includes vitamin which belongs to water-soluble 
vitamin B complex (Biothinum or vitamin Н).  Biothinum has 
an impact on metabolic processes, takes part in carboxylation, 
decarboxylation, deamination of proteins and carbohydrates, 
assists in lipids metabolism and is considered to be an impor-
tant component necessary for neurotrophic processes and cell 
differentiation [6, 10].
Biothinum takes part in the formation of keratin, neces-
sary for hair matrix and nail plate development, contributes 
to the improvement of its structure and growth, brings off 
signs of early hair depigmentation.  Biothinum is a source 
of sulphur which contributes to collagen formation exerting 
a positive impact on the structure of skin and its accessory 
organs (hair, nails) and normalizing sebaceous gland function. 
This Biothinum potential can be used for the reduction of ag-
ing processes intensity and for skin changes renewal [2, 10].
The aim of this research is to evaluate the efficacy of thera-
peutic complex which includes systemic antimycotic and vita-
min agent Wolvit produced by Kusum Healthcare PVT LTD, 
India in the treatment of onychomycoses on fingers and toes. 
Material and methods
We observed 43 patients with onychomycosis of fingers 
and toes aged from 34 to 75.  The diagnosis was confirmed 
by microscopic examination.  The patients were divided into 
two groups: main and control groups.  The treatment of all 
the patients was carried out at the department of dermatol-
ogy, infectious and parasitic skin diseases at Institute of Der-
matology and Venereology of National Academy of Medical 
Sciences of Ukraine.
Prior to treatment all the patients underwent comprehen-
sive clinical laboratory investigation.  All the patients before 
and after the treatment underwent examination to determine 
complete blood cell count (the level of hemoglobin, erythro-
cytes, leukocytes and blood sedimentation rate), urine analysis 
(to determine its specific gravity, рН, protein, sugar, leuko-
cytes, erythrocytes, casts) and evaluation of liver function 
(determination of alanine aminotransferase, serum glutamic 
oxalacetic transaminase, glucose level, total bilirubin and total 
protein, an indicator of synthetic ability of the liver) [3, 11].
Mycologic examination of nail plates in patients of both 
groups was rendered by the method of microscopic evaluation 
of unstained preparations with prior processing (clearing) 
of material under investigation.  Pathologic material was 
collected and microscopically examined before the onset of 
treatment and on the fourth, sixth, eighth, tenth, twelfth and 
sixteenth weeks of treatment [1].
Every other week before, after and during treatment 
each patient underwent evaluation of subjective signs of 
the disease (itching, soreness), objective examination data 
(measurement of nail plate length from nail fold to distal 
end,  oozing lesions, hyperemia, exfoliation, dryness of skin, 
cracks, microscopic examination of nail plates).  Recording 
of objective signs indicating nail plate disorders was carried 
out before and after the treatment according to the follow-
ing characteristics: distal impairment, lateral impairment, 
and total impairment with the involvement of growth plate, 
total impairment without the involvement of growth plate, 
subungual hyperkeratosis, onycholysis, alteration of healthy 
nail plate growth.  Sign manifestation rate was evaluated by 
the following scale:
0 – Absence of sign;
1 – Slight manifestation rate;
2 – Moderate manifestation rate;
3 – Significant manifestation rate.
The main group comprised 33 persons: 15 men and 
18 women, who received comprehensive treatment, which 
included systemic antimycotic drug and agent Wolvit.  The 
disease duration in patients who took part in the investigation 
constituted from 2 months to 10 years. 
Systemic antimycotic was used according to the schedule 
in compliance with the instructions. Wolvit was administered 
in the dosage of 5 mg once a day before meals during the 
whole course of treatment with systemic antimycotic.  The 
course of treatment with systemic antimycotic comprised 
1.5 months in onychomycosis of fingers and 3 months in 
onychomycosis of toes.
The control group included 10 persons: 2 men (20%) and 
8 women (80%).  The patients of this group were treated with 
systemic antimycotic.  The course of treatment with this drug 
agent comprised 1.5 months in onychomycosis of fingernails 
and 3 months in onychomycosis of toenails.
Results and discussion
Potency assignment of the complex under investigation 
was carried out on the ground of results, obtained in clini-
cal and mycologic investigations.  Clinical judgment of the 
method included evaluation of complaints and dynamics of 
objective disease manifestations.  Mycologic efficiency con-
sisted in fungi elimination.
The patients of both groups demonstrated positive dy-
namics of skin process in the course of treatment: itching 
and soreness were found to decrease significantly, as well as 
hyperemia, exfoliation and maceration.  Five patients with 
mycosis of feet and onychomycosis were found to have ac-
tive epithelialization of cracks and patients with dyshidrotic 
type of disorder were found to reduce the appearance of new 
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vesicular elements, the previously developed vesicles became 
dry and started to flake off.
Of 24 patients who belonged to the main group with 
complaints of soreness, 14 patients (46.6%) were found to 
have regression of soreness on the 4th week, 5 patients (16.6%) 
on the 6th week and five patients (16.6%) on the 8th week of 
treatment.
Itching was completely absent in 9 patients of the main 
group (4 men and 5 women).  Of 21 patients who belonged 
to the main group with complaints of itching of the feet prior 
to treatment and in 10 patients (33/3%) it disappeared on the 
4th week of treatment and in the same number of patients on 
the 6th week.  In one patient (3.3%) itching persisted till the 
8th week of treatment. 
Subjective signs regression in the control group was obser-
ved later.  Absence of subjective signs constituting itching and 
soreness was noted in 1 patient of the control group (10.0%).
Of 9 patients who complained of soreness, 1 patient (10%) 
was found to have a regression on the 2nd week of treatment, 
two patients (20%) on the 4th week and in three patients (30%) 
on the 6th week of treatment.  In two patients (20%) of the con-
trol group soreness disappeared on the 8th week and persisted 
till 12 weeks of treatment in one patient (10%). 
Of 5 patients with complaints of foot itching, two patients 
(20%) were found to overcome it on the 4th week of treatment 
and three patients on the 6th week (30%). 
The structure of impaired nail plates in all the patients 
started to improve during the course of treatment: it acquired 
light pink color, its surface became glossy and smooth, free 
edge of nail plates became flatter and thicker.  Nails started 
to acquire normotrophic structure.
Data are represented in table 1.
Studying the data provided in table 1 it is possible to note 
that soreness regressed 1.1-fold quicker on the 4-8th weeks of 
Table 1
The dynamics of subjective signs in patients of the main and control group during the course of treatment
Subjective signs
Main group (n-33) Control group (n-10)
4 wk 6 wk 8 wk 10 wk 12 wk 4 wk 6 wk 8 wk 10 wk 12 wk
Soreness 14 5 5 - - 2 3 2 - 1
% 42.4% 15.1% 15.1% - - 20% 30% 20% - 10%
Itching 10 10 1 - - 2 3 - - -
% 30.3% 30.3% 3.03% - - 20% 30% - - -
treatment in patients of the main group than in the control 
group.  Full regression of soreness was observed in patients 
of the main group on average on the 8th week and in patients 
of the control group on the 12th week.  Regression of itching 
was noted to be 1.3-fold quicker on the 4th and 6th week of 
treatment in patients of the main group than in patients of 
the control group.  Full regression of itching was observed 
in all the patients of the main group on the 8th week and in 
the patients of the control group it was seen on the 6th week 
of treatment.
Nail plate length from nail fold to distal edge was measu-
red prior to the study and the second, fourth, sixth, eighth, 
twelfth and sixteenth weeks of treatment in order to assess the 
dynamics of nail plate regrowth in patients of both groups. 
Student-Fischer test was applied for independent samples in 
order to compare the indices of the main and control groups. 
Data are represented in table 2.
Comparison of the indices shown in table 2 show that nail 
plate regrowth index in the control group comprised 0,42 ± 
0,03 whereas in the main group it was 0.98 ± 0.03, which im-
plies that the amount of time necessary for nail plate regrowth 
reduced by 2.3-fold in patients of the main group. 
Full clinical remission and elimination of fungi from the 
affected nail plates in the course of treatment with therapeu-
tic complex including systemic antimycotic and “Wolvit” in 
patients of the main group were observed on the 8th week in 
one patient with onychomycosis of fingernails which com-
prised (3.03%), on the 12th week in the majority of patients of 
the main group, namely 21 patients, which comprised 57.6% 
and on the 10th week in 10 patients (27.3%).  And only in one 
patient (3.03%) negative reaction of mycologic microscopic 
examination occurred on the 16th week of the treatment.
Table 2
The assessment of nail plate growth rate in patients of 
the main and control groups
Subjective 
sign










0.40 ± 0.05 1.38 ± 0.06 0.98 ± 0.03
Control group
(n-10)
0.71 ± 0.08 1.13 ± 0.08 0.42 ± 0.03
* we refer to the site of the nail plate without clinical signs of 
onychomycosis (changes of structure, color and so on)
Full clinical remission and elimination of fungi from nail 
plates in patients of the control group who received only 
systemic antimycotic occurred at the same extent on the 12th 
and 16th weeks of treatment and there were five patients (by 
50%) in each one.  Negative reaction in the pathologic material 
of the patients still did not occur on the 10th week.  Data are 
represented in table 3.
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Table 3













6 weeks - - - -
8 weeks 1 3.03 - -
10 weeks 10 27.3 - -
12 weeks 21 57.6 5 50.0
16 weeks 1 3.03 5 50.0
The comparison of indices, given in table 3 shows the 
acceleration of mycologic negative reaction in the patients 
of the main group.
The assessment of agent acceptability was carried out on 
the basis of subjective symptoms and sensations, reported by 
the patients and objective evidence, obtained in the course of 
treatment, based on laboratory indices dynamics as well as on 
the rate of occurrence and character of adverse reactions.  The 
patients tolerated the treatment well, only one patient from 
the main group developed nausea on the 4th day of therapeutic 
complex administration but it did not require cancellation 
of agent intake.  Patients of the both groups did not seem to 
develop any adverse allergic reactions.
The assessment of liver function following the termination 
of the course of treatment determined the absence of any sig-
nificant changes in biochemical factors of blood in all the pa-
tients of the both groups.  Clinical blood analysis and clinical 
urine analysis showed that fluctuations of indices in patients 
after the course of treatment did not exceed the normal rate.
Summing up the above mentioned, it is possible to su-
ggest that the complex comprising systemic antimycotic and 
“Wolvit” shows good tolerability, does not cause any adverse 
or allergic reactions and is easy to use (it is sufficient to take 
it once a day).  The administration of vitamin agent “Wol-
vit” together with systemic antimycotics allows to achieve a 
significant improvement of nail plate structure as it acquires 
even light pink translucent color, glossy surface, smooth 
and thick free edge, normotrophic structure.  Participation 
of biothinum in the formation of keratine, necessary for the 
development of hair matrix and nail plate, results in accelera-
tion of healthy nail growth in patients with onychomycoses. 
Biothinum is also a source of sulphur, which transports 
sulphur into the skin and its accessory organs, contributing 
to collagen formation and therefore eliminates signs of early 
hair depigmantation, normalizes sebaceous glands function 
and exerts a positive impact on the structure of skin and its 
accessory organs (hair, nails).
Conclusions
The developed complex with the employment of systemic 
antimycotic and agent “Wolvit” can be recommended for use 
in the treatment of dermatologic diseases as a current complex 
method for effective treatment of onychomycoses of finger-
nails and toenails, which gives a possibility:
- To achieve clinical remission as well as elimination of 
the causal organism and improvement of nail plate structure 
within a shorter period of time;
- To reduce the amount of time necessary for nail plate 
regrowth.
References
1. Araviysky RА, Gorshkova GI. Praktikum po meditsinskoy mikologii [A 
practical work in Medical Mycology]. SPb.: Izd-vo SPbMAPO [Publishing 
house SPbMAPO], 1995.
2. Кirichek LT. Vitaminy, kak sredstva farmakoterapii [Vitamins as Phar-
macotherapy drugs]. Doctor. 2002;6:79-82.
3. Kolb VG, Kamyshnikov VS. Spravochnik po klinicheskoy khimii [Refer-
ence book in Clinical Chemistry]. Minsk: Belarus, 1982.
4. Kolyadenko VG, Korolenko VV. Suchasni uiavlennia pro terapiiu pry 
onikhomikozakh [Modern view on onychomycosis therapy]. Ukrainskyi 
zhurnal dermatolohii, venerolohii, kosmetolohii [Ukrainian journal of 
Dermatology, Venerology, Cosmetology]. 2008;6:65-69.
5. Kutasevych YaF, Mashtakova IA, Bezruchenko IА. Novyie vozmozhnosti 
v lechenii gribkovyih porazheniy kozhi [New abilities in treatment of 
mycotic skin lesions]. Ukrainskyi zhurnal dermatolohii, venerolohii, 
kosmetolohii [Ukrainian journal of dermatology, venereology, cosmetol-
ogy]. 2008;9:80-82.
6. Kutasevych YaF, Pyatikop ІО, Zimina ТV, et al. Suchasne likuvannia 
onikhomikoziv. Metodychni rekomendatsii [Modern treatment of ony-
chomycoses. Guidelines]. Kharkiv, 2000.
7. Kutasevych YaF, Zimina TV. Sovremennaya strategiya lecheniya 
onihomikozov [Modern strategy of onychomycosis treatment]. Zhur-
nal dermatologii i venerologii [Journal Dermatology and Venerology]. 
1999;2(8):54-55.
8. Leschenko VM. Onihomikozy [Onychomycoses]. Consilium Medicum. 
2005;7(1):27-31.
9. Sergeev YuV, Sergeev AYu. Onihomikozyi. Gribkovyie infektsii nogtey 
[Onychomycoses. Mycotic infections of nails]. Moscow: Geotar Medi-
cine, 1998.
10. Tishchenko LD. Vitaminyi v dermatologii [Vitamins in Dermatology]. 
Moscow, 1987.
11. Franklin Т, Snow J. Biohimiya antimikrobnogo deystviya: Perevod s 
angliyskogo [Biological chemistry of antimicrobial action: Translation 
from English]. Мoscow: Mir [World], 1984.
12. Baran R, Dawber RPR, Haneke E, et al. A Text Atlas of Nail Disorders. 
Techniques in Investigation and Diagnosis. Third edition. Taylor & 
Francis, 2003;343.
